The efficiency of antileishmanial agents may be enhanced by improving their bioavailability with a colloidal drug carrier. We 
INTRODUCTION

L eishmania
are obligatory intracellular parasites of mononuclear phagocytic cells of man and other vertebrates. Because the mononuclear phagocytic system of liver, spleen and bone marrow are able to clear particles from the circulation visceral leishmaniasis has been considered the ideal disease for passive drug targeting.
The number of cases of leishmaniasis refractory to the usual treatment is now increasing (Croft et al., 1991) . This can be linked not only to the genetic nature of some strains, but also to the immunodepressed state of some patients (Croft et al., 1991; Thakur et al., 1991) . The treatment with pentamidine is not fully effective and has toxic side effects, nevertheless it is used (Soto et al., 1994) . Colloidal drug carriers bound to pentamidine could enhance effi- et al., 1988 et al., -, Chiannikulchai et al., 1989 or antibiotics (Fattal et al.. 1989) . Furthermore, another kind of nanoparticles prepared from biodegradable polyisobutylcyanoacrylate polymers, has shown in vitro activity against African trypanosomes (Lherm et al., 1987) and the extracellular Leishmania amastigotes (Bories et al., 1991) . This property was tested in our laboratory within an in vitro model using the monohistiocy- The loaded and unloaded nanoparticles were injected via the tail vein.
The method for treating experimental visceral leishmaniasis in mice was an adaptation of the model of Neal et al. (1985) . The different groups are presented in Table I .
INOCULATION OF BALB/C MICE
The infective promastigotes were centrifuged at 700 g for 10 min. The pellet was resuspended in normal saline. It was homogenized and adjusted to 4xl0 7 promastigotes in a volume of 0.1 ml.
The injection was strictly intravenous, via the tail vein.
In this model, 12 days after initial infection, visceralization was obtained. Drug dosing was performed on days 13. 15. and 17 (days 13, 14, 15, 16, and 17 for the Glucantime®).
At day 21. after initial infection, the animals were killed by cervical dislocation. Mice were weighed, livers and spleens were removed and also weighed.
Smears were prepared from livers and spleens. A liver sample was prepared for an electronic microscope study.
After Giemsa staining of the smears, the liver parasite burden (I) was calculated from the number of amastigotes/500 hepatocytes and related to the liver weight (P in mg), following the Stauber formula (Stauber L.A. et al., 1958) .
The parasite suppression (Y) was calculated from the ratio of the mean amastigote counts in drug treated groups to the mean amastigote counts in untreated control group ( 100 % of the parasite burden).
STATISTICAL ANALYSIS
Since data did not show equal variances (F-test) and since a gaussian distribution was not demonstrated for all experimental groups, the non-parametric MannWithney U-test was routinely used to test the null hypothesis. Alternatively, equal variances and normal distribution were obtained after log transformation of the data, thus permitting the use of t-test and variance analysis (N.T. BAILEY, 1992) . Similar significance levels were obtained using both procedures. A twotailed P value < 0.05 was considered as significant. Table I -Experimental treatment groups * Each group contained 10 mice except 12 mice for group 3 † Pentamidine dosages were expressed in base. * Administered polymer was 12.5 mg kgx3 d. throughout. § Prepared extemporaneously into syringe by mixing unloaded nanoparticles suspension and pentamidine isethionate solution. After necropsy, the liver parasite burden in infected control group was, on average, 12.94 x 10 8 amastigotes (Table II) respectively vs untreated group). However, the difference between the two regimens (P = 0.975) was not significant. The parasite suppression was higher when mice were treated with pentamidine-bound nanoparticles than with pentamidine alone (77 % vs 35 %, P = 0.0003). However, pentamidine-bound nanoparticles were less efficient than Glucantime® (86 % versus 77 %, P = 0.0026). Unloaded nanoparticles had no effect since the amastigote count was similar to the control (group 1 vs group 4 P = 0.14).
ACTION OF PERTAMIDINE-BOUND NANOPARTICUS AGAINST LEISHMANIA
RESULTS
F
When free-pentamidine and nanoparticles were mixed just before administration, amastigote counts were close to those obtained with pentamidinebound nanoparticles but a large variation was observed between animals (Table II) . Table II -Suppression of experimental leshmaniasis in mice treated with free pentamidine and pentamidine bound-nanoparticle.s The suppression percentage was calculated using the Stauber count vs. untreated mice (group 1) as described in the experimental section. Data are mean ± standard deviation for 10 mice per group, except group 3 (n = 12). * P < 0.01 vs. untreated mice (group I) ; ** P < 0.001 vs. untreated mice : § P < 0.001 vs. peniamidine-nanoparticles treated mice (group 3) concentration, the nanoparticles would not be loaded homogeneously. In vitro, the efficiency of 50 pM pentamidine loaded nanoparticles was reduced despite an increase of the number of loaded nanoparticles.
CHOICE OF THE PARTICULATE DRUG CARRIER
Intracellular sustained-release form is an interesting concept for treatment of mononuclear phagocytic system parasites.
Various drug carriers have already been tested, all of which have advantages and disadvantages. Croft el al. (1991) using liposomes loaded with amphotericin B (Ambisome®) obtained good results both in vitro and in vivo and in man. Various colloidal drug carriers have also been tested. Cyanoacrylate-based nanoparticles are biodegradable, which is an important consideration for a product injected intravenously. However, in-vitro, their are often toxic to mammal cells (Deniau et al., 1993) . Unloaded polyisoalkylcyanoacrylate nanoparticles have a specific action on Kinetoplastidae e.g. Trypanosoma brncei (Lherm et al., 1987) , Leisbmania donovani (Gaspar et al., 1992; Bories et al., 1991) . They have been linked with primaquine, doxorubicine and dehydroemetine, in order to destroy intracellular Leisbmania (Rodrigues et al., 1994; Fouarge etai, 1989) .
Biodegradable polymer (polylactide) and copolymer (glycolactide) have a number of free carboxylic groups lower than polymethacrylate ones and the pentamidine-binding yield is lower. A previously binding study of pentamidine with these biodegradable polymers was realized, only 20 % of the dose (100 pM) was bound (unpublished data).
Polymethacrylate nanoparticles are slowly biodegradable (Astier et al., 1988; Paul, 1990 ), but they are harmless. When unloaded, they have no leishmanicidal activity. They are entrapped by the parasited cells, but their presence in the cells did not seem to have any effect on parasite load, as was confirmed in this experiment.
Previous studies have shown that these nanospheres exhibited methacrylic acid residues on their surface which could form ionic bonds with pentamidine. This stoichiometric binding is stable above pH 6.5. In the phagolysosome the pH is about 5.5. Consequently, after phagocytosis pentamidine could be released from its carrier inside the lysosome. This quality is particularly interesting in the case of leishmaniasis and electron microscopy has demonstrated the uptake of nanospheres by parasitised cells (unpublished data).
HYPOTHESIS ON THE MECANISM OF ACTION
Antileishmanial activity was obtained in our model with a dose of targeted pentamidine twelve-time less than the usually prescribed dose. However, the nanoparticles mode of action remains unclear. The nanoparticles loaded with leishmanicidal molecules can be efficient through the releasing of drugs on the target, which is the aim of targeting. The pentamidine, after release inside the cells, could act on the mitochondrion and the kinetoplaste of the parasite. The hypothesis of penetration of loaded carriers through the flagellar pocket is not possible in case of methacrylate polymer because of the big size of nanospheres.
A study in electronic microscopy has shown that in Our results confirmed that particular unloaded nanoparticles are neither active nor toxic.
The most interesting results were the efficacy of pentamidine-bound nanoparticles which approached the efficacy of Glucantime®.
In the group receiving both free pentamidine and unloaded nanoparticles. a relative efficacy was obser- 
